Table 1

Baseline characteristics

Patients with immune-mediated inflammatory disorders on immunsuppressantsControls
(n=1593)(n=579)
With SARS-CoV-2 omicron breakthrough infection
(n=472)
Without SARS-CoV-2 omicron breakthrough infection (n=1121)With SARS-CoV-2 omicron breakthrough infection (n=181)Without SARS-CoV-2 omicron breakthrough infection (n=398)
 Group—no (%)
 Patients with IMID472(100)1121(100)126(70)292(73)
 Healthy controls55(30)106(27)
Patient characteristics
 Age, years—mean (SD)46(13)53(13)48(13)53(11)
 Female sex—no (%)317(67)675(60)128(71)261(66)
Comorbidities—no (%)
 Cardiovascular disease37(8)113(10)6(4)30(9)
 Chronic pulmonary disease19(4)93(8)3(2)17(5)
 Diabetes13(3)56(5)3(2)13(4)
 Obesity195(42)553(50)75(42)182(46)
 Missing000026(14)51(13)
IMID type—no (%)
 Rheumatological diseases157(33)425(38)22(12)44(11)
  Rheumatoid arthritis53(11)181(16)8(4)13(3)
  Spondylarthritis29(6)71(6)7(4)12(3)
  Systemic lupus erythematosus53(11)100(9)3(2)11(3)
  Other rheumatological*22(5)73(7)4(2)8(2)
 Neurological†140(30)307(27)42(23)120(23)
 Gastroenterological‡127(27)246(22)22(12)68(17)
 Dermatological§48(10)143(13)39(22)58(15)
Immunosuppressants—no (%)¶
 Other immunosuppressants192(41)502(45)
 MTX58(12)225(20)
 TNF-inhibitors100(21)180(16)
 Anti-CD2064(14)129(12)
 MMF27(6)56(50)
 S1P modulator31(7)29(26)
Prior SARS-CoV-2 infection—no (%)
 Any infection prior omicron wave78(17)266(24)38(21)120(30)
 Two infections prior to omicron wave1(0.2)4(0.4)1(0.6)3(0.8)
Additional vaccination prior to SARS-CoV-2 omicron—no (%)
 Any additional vaccination387(82)1016(91)134(74)356(89)
 Two additional vaccinations62(13)170(15)004(1)
 Available humoral response data after primary vaccination—no (%)n=431n=1026n=158n=346
 Seroconversion354(82)896(87)154(97)342(99)
  • Table showing baseline characteristics of participants divided into patients with immune-mediated inflammatory disorders on immunosuppressants and controls (patients with immune-mediated inflammatory diseases not on immunosuppressants and healthy controls), with and without a SARS-CoV-2 omicron breakthrough infection.

  • *Including vasculitis (small-vessel, medium-vessel and large-vessel vasculitis and other forms of vasculitis except giant cell arteritis), other rheumatological (giant-cell arteritis, polymyalgia rheumatica and others).

  • †Multiple sclerosis and neuromyelitis optica spectrum disorder, Inflammatory neuropathies and myopathies (chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy and inflammatory myositis), myasthenia gravis.

  • ‡Crohn’s disease, ulcerative colitis, autoimmune hepatitis, other inflammatory bowel disorders (autoimmune hepatitis, autoimmune sclerosing cholangitis).

  • §Atopic dermatitis, psoriasis, pemphigus, other dermatological (vitiligo, pemphigus, psoriasis and others); e: anti-CD20 therapy, sphingosine-1-phosphate receptor (S1P) modulators and MMF.

  • ¶Therapies are either monotherapy or combination therapy, calculated percentage of total patients with IMID treated with a type of immunosuppressant.

  • IMID, immune-mediated inflammatory disease; MMF, mycophenolate mofetil; MTX, methotrexate; S1P, sphingosine-1-phosphate receptor; TNF-inhibitor, tumour necrosis factor inhibitor.